Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: A safe approach for radical resection

Annals of Surgery

Volumn 247, Issue 4, 2008, Pages 659-665

  Kianmanesh, Reza ^a   Sauvanet, Alain ^a   Hentic, Olivia ^a   Couvelard, Anne ^a   Lévy, Philippe ^a   Vilgrain, Valérie ^a   Ruszniewski, Philippe ^a   Belghiti, Jacques ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOCRINE TUMOR; FEMALE; FOLLOW UP; HUMAN; INTESTINE CANCER; KAPLAN MEIER METHOD; LENGTH OF STAY; LIVER HYPERTROPHY; LIVER METASTASIS; LIVER RESECTION; LIVER SURGERY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PORTAL VEIN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECTUM CANCER; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; VEIN LIGATION;

ADULT; AGED; DIGESTIVE SYSTEM NEOPLASMS; ENDOCRINE GLAND NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 41149144053     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31816a7061     Document Type: Article

References (45)

1. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445.
2. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
3. Dousset B, Saint-Marc O, Pitre J, et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg. 1996;20:908-914.
4. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-1063.
5. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control. 2002;9:67-79.
6. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12:231-242.
7. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394-424.
8. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375-382.
9. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240:1037-1049.
10. Kianmanesh R, Farges O, Abdalla EK, et al. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg. 2003;197:164-170.
11. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078-1085.
12. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783.
13. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422-427.
14. Ahlman H, Friman S, Cahlin C, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265-269.
15. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
16. Amarapurkar AD, Davies A, Ramage JK, et al. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol. 2003;15:139 -143.
17. Chu QD, Hill HC, Douglass HO, Jr., et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9:855-862.
18. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;73:386-394.
19. Rodallec M, Vilgrain V, Zins M, et al. Helical CT of pancreatic endocrine tumors. J Comput Assist Tomogr. 2002;26:728-733.
20. Hirono S, Tani M, Kawai M, et al. Indication of hepatopancreatoduodenectomy for biliary tract cancer. World J Surg. 2006;30:567-573.
21. Shibata T, Yamamoto Y, Yamamoto N, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol. 2003;14:1535-1542.
22. Thomas KT, Bream PR, Jr., Berlin J, et al. Use of percutaneous drainage to treat hepatic abscess after radiofrequency ablation of metastatic pancreatic adenocarcinoma. Am Surg. 2004;70:496-499.
23. de Baere T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181:695-700.
24. Roche A, Girish BV, de Baere T, et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology. 2004;51:1751-1756.
25. Huang SF, Ko CW, Chang CS, et al. Liver abscess formation after transarterial chemoembolization for malignant hepatic tumor. Hepatogastroenterology. 2003;50:1115-1118.
26. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-78.
27. Yigitler C, Farges O, Kianmanesh R, et al. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl. 2003;9:S18-S25.
28. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675-680.
29. Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859-866.
30. Di Stefano DR, de Baere T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology. 2005;234:625-630.
31. Elias D, Santoro R, Ouellet JF, et al. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51:1788-1791.
32. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-851.
33. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743-751.
34. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001;25:689-692.
35. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208-217.
36. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225:355-364.
37. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307-1312.
38. Olausson M, Friman S, Cahlin C, et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg. 2002;26:998-1004.
39. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8:208-212.
40. Fenwick SW, Wyatt JI, Toogood GJ, et al. Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg. 2004;239:210-219.
41. Le Treut YP, Gregoire E, Belghiti J, et al. Liver Transplantation for endocrine metastases: location of the primary tumor and liver size are predictors for survival. A French multicentric 85-case series. Am J Transplant. 2007;7:213(abstract).
42. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677-682.
43. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170-175.
44. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
45. Maire F, Hammel P, Hentic O, et al. Is adjuvant therapy useful after resection of liver metastases of digestive endocrine tumors? Gastroenterology. 2007;132:AS2071 (abstract).